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from start of study drug administration. Dose escalation 
decision and recommended dose (RD) were made by an 
independent safety committee. Blood PK and PD samples 
were serially drawn along the 3 cycles. 
 
Results: Fourteen patients were included in the study. DLTs 
per dose level (DL) are shown in the table with 3 patients 
experiencing more than one DLT. The RD of Debio 1143 to be 
combined with CRT was 200 mg/day (=MTD). Debio 1143 
exposure increased proportionally with dose and did not 
accumulate over time. Amylase/lipase and ALT/AST increase 
was associated with higher Debio 1143 exposures. At all dose 
levels, the PD effect of Debio 1143 was evidenced by the 
degradation of cIAP1 in PBMCs and a trend in an increase of 
serum MCP1. 12 patients were evaluable for response by 
RECIST 10-12 weeks post treatment among which 3 CR, 5 PR 
and 1 SD.  
 
 
Conclusion: Combination of Debio 1143 with CRT was 
tolerated, exhibited favourable PK in combination with CRT 
with significant PD activity. The MTD was found to be 200 
mg/day and is now being used in a randomized phase 2 study 
initiated by GORTEC to evaluate the anti-tumor activity of 
this combination in LA-SCCHN. 
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Purpose or Objective: Study of pharmacokinetics (PK), 
toxicity, and compliance with nimorazole (NIM) which is 
currently investigated for its efficacy in three large 
randomized clinical trials (NIMRAD, EORTC 1219/DAHANCA 
29, and DAHANCA 30) 
 
Material and Methods: The PK of NIM was studied in 63 
patients with HNSCC treated in the DAHANCA-5 trial. While 
the toxicity and compliance were studied in HNSCC patients 
treated with NIM, in combination with radiotherapy (RT) or 
chemo-radiotherapy (CRT), in Denmark between 1990 and 
2013. Plasma concentration measurements were done using 
high pressure liquid chromatography following the first day 
dose; and plasma concentration profiles were subjected to 
non-compartmental PK analysis using validated PC-based 
software. The different PK parameters were calculated and 
correlated with the different patient- and treatment-related 
variables. Nimorazole was administered as oral tablets in 
doses of approximately 1.2 g/m² BSA before the first daily 
radiation treatment. A second dose of 1 g was given before 
the second RT fraction in the accelerated fractionation 
regimen (6 fractions/week). The compliance was estimated 
as the percentage of the initially prescribed dose; and drug-
related side effects were reported from the DAHANCA 
database. 
 
Results: A linear relationship between peak plasma 
concentration and administered dose was detected. The 
mean peak concentration was 36.8 ± 1.3 µg/ml, and the time 
of peak concentration ranged between 30 and 180 min 
(median 60 min). Plasma elimination occurred with a mean 
half-life of 3.35 ± 0.09 h. There was a statistically significant 
correlation between area under the concentration-time curve 
(mean 191 ± 6 µg·h/ml) and administered dose, especially 
when expressed as g/m². A statistically significant longer 
elimination half-life in men relative to women (mean 
difference 0.40 h; 95% confidence interval 0.77-0.03; P 0.03) 
was detected. A total of 1049 patients were investigated for 
toxicity and compliance with NIM. The compliance was fair, 
with both conventional and accelerated RT as well as CRT 
schedules, with 58% of patients received the full prescribed 
total dose. Nausea and vomiting were the major complaints 
representing 87% of the known side effects that caused dose 
reduction. All side effects ceased when treatment was 
interrupted, and neither severe nor long lasting side effects 
were observed. Female patients, and patients received 
accelerated CRT were significantly less compliant with NIM, 
and more likely to have nausea and vomiting; while patients 
who received less than 1100 mg/m² per day were 
significantly more compliant, and less likely to have nausea 
and vomiting. 
 
Conclusion: The current nimorazole administration practice 
in clinical trials is acceptable, and the compliance to the 
drug is fair, either with the conventional or accelerated RT as 
well as CRT, with tolerable acute, but neither persistent nor 
late, toxicity. 
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Purpose To demonstrate that dose painting (DP) is a 
promising tool to decrease overall treatment time (OTT), to 
reduce toxicity, to improve palliation or enhance tumor 
control. The present state of DP will be illustrated through 3 
types of applications. We will also speculate about the 
potential of DP to integrate with novel systemic treatment 
approaches.  
Materials and methods  
A. Topographical DP (TDP) in breast irradiation. TDP 
distributes dose as function of the spatial distribution of 
subclinical cancer deposits nearby the primary tumor in 
breast cancer. Patients (n=170) were randomized between 
prone whole breast irradiation (WBI) followed by a boost 
(WBI-SeqB: OTT=4 weeks) and WBI with simultaneous 
integrated boost (SIB) using TDP (WBI-TDP-SIB: OTT=3 
weeks). Acute moist desquamation rate was the primary 
endpoint.  
B. DP against bone metastasis pain. There is no dose-response 
relationship above 8 Gy single dose for the control of pain by 
uncomplicated bone metastases. This observation triggered 
the hypothesis that cytokine cascades counteracting 
palliation are activated by radiation and that their activity is 
function of the irradiated volume. DP was employed to 
drastically reduce the irradiated volume. Patients (n=45) 
were randomly assigned (1:1:1) to receive a single fraction of 
either 8 Gy with conventional radiotherapy (Conv-8Gy) or 8 
Gy with DP (dose range 6-10 Gy) (DP-8Gy) or 16 Gy with DP 
(dose range 14-18 Gy) (DP-16Gy). The trial was designed for 
selection of the experimental arm worthwhile of continuing 
in phase III.  
C. DP in loco-regionally advanced head&neck cancer. 18F-
FDG-PET-guided DP-treated patients enrolled in 3 dose-
escalation studies (n = 72) were matched with standard IMRT-
treated patients (n=72) irradiated during the same time 
period. Median dose in the DP-group was 70.2-85.9 Gy/30-32 
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fractions against 69.1 Gy/32 fractions in the IMRT group. 
Endpoints were local control, acute and late toxicity.  
Results A. Interim analysis (n = 150) showed low rates of 
moist desquamation, mostly located in the infra-mammary 
fold (5/75 WBI-SeqB vs 3/75 WBI-TDP-SIB, p =0.5). Trends in 
favor of WBI-TDP-SIB were observed for breast edema 
(p=0.08) and pruritus (p = 0.1). B. The volume of normal 
tissue receiving 4 Gy, 6 Gy and 8 Gy was at least 3, 6 and 13 
times smaller in the DP-8Gy arm compared to Conv-8Gy and 
DP-16Gy (p<0.05). DP-8Gy resulted in a pain response of 80% 
compared to 53% and 60% for Conv-8Gy and DP-16Gy. Quality 
of life analysis suggests better outcome for patients treated 
in the DP-8Gy arm with the scores ‘painful characteristic’, 
‘insomnia’ and ‘appetite loss’ reaching significance (p<0.05). 
C. Local control at 5 y was 83.4% and 75.2% in the DP- and 
IMRT-treated patients, respectively (p=0.28). Grades of acute 
dysphagia and mucositis were higher for the DP- than for the 
IMRT-treated group (p=0.03 and p=0.08, respectively) but 
differed according to DP-technique and –prescription. Poorly 
healing mucosal ulcers at the locations of the highest doses 
were observed in 9 DP- and 3 IMRT-treated patients (p=0.07) 
and reflect dose-limiting toxicity (DLT). Analysis of all DP-
treated patients showed that DP-planning using a linear 
relation between 18F-FDG voxel-intensity and dose was 
associated with high risk of DLT if peak-doses were >84 Gy or 
the volume receiving >80 Gy was >1.75 cc in 30-fraction 
schedules (OTT = 6 weeks). Discussion and conclusions  
The term DP covers a variety of techniques that open a vast 
spectrum of applications.The use of TDP after breast-
conserving surgery allows to integrate boost treatment in WBI 
without increasing toxicity. In bone metastasis, DP-8Gy was 
selected as a candidate experimental arm to test the 
hypothesis of improved palliation by reducing the irradiated 
volume. A confirmatory phase III trial is underway. In loco-
regionally advanced head&neck cancer, DP may open a 
window for improving local control. However, the safety 
margin for dose-escalation is narrow. Poorly healing mucosal 
ulcers at the peak-dose regions are DLT of DP. The 
dose/volume/DLT relationship casts doubt on the safety of 
linear 18F-FDG voxel-intensity based DP. A phase III trial 
using non-linear DP is underway. Tumor heterogeneity –
known for decades- supports DP and refutes the use of 
homogeneous dose distributions. Dose escalation to 
radioresistant regions in the tumor or decreasing the 
irradiated volume may be a conceptually naive way to use 
DP. The insight that ionizing radiation can enhance vascular 
and immunogenic mechanisms of cell death opens a new field 
for DP characterized by large fraction doses to small sub-
volumes of tumor. In these applications, direct cancer cell 
kill might be subordinate to other goals of DP including 
amplifying bystander and abscopal effects or breaking 
immune tolerance. Combination of DP with 
immunomodulating drugs or drugs that target vasculature or 
immune checkpoints are investigated to validate these 
concepts. 
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Any additional dose that can be applied without harm will lift 
tumour control in a patient population. Dose painting (DP) 
claims to make better use of dose than an indiscriminate or 
random escalation: by virtue of functional imaging, it should 
be more effective, more selective and more patient-specific. 
Still, on a pragmatic level, DP can often be summarized by 
“we boost because we can”. What does it take to go more 
biological?  
Obstacles lie in quantitative functional image acquisition, 
image interpretation, dose prescription and collection of 
evidence. Unfortunately, quantitative functional imaging is 
notoriously capricious. The problems tend to grow the more 
specific in terms of tumour biology an imaging modality is - 
which is one of the reasons for the popularity of FDG-PET, 
being arguably one of the least specific modalities. A specific 
modality may be more intriguing scientifically, but obviously 
shows only a narrow aspect of tumour biology, which may 
create a need for a combination of multiple modalities. 
Imaging modalities usually operate at length scales far 
greater than the phenomena to which they are sensitive. This 
can make the interpretation of images challenging, especially 
when tracer kinetics need to be considered. Imaging 
sophistication alone reveals little of the import of some 
physiological or biological trait for treatment outcome. Only 
clinical data can fill this gap in biological understanding with 
some confidence. Further, a single image is just a snapshot of 
a dynamically evolving tumour, and if taken pre-treatment, 
says little about the tumour´s response to therapy. 
Therefore, without any highly suggestive clinical evidence, 
the prospects for naive (i.e. model-based) DP are bleak.  
Accordingly, the majority of DP trials to date are pragmatic 
in their choice of imaging modality and –protocol, and dose 
prescription. In addition to being practical, especially in a 
multi-centric setting, this also ensures that a proof of benefit 
(of both boosting and imaging) can eventually be made. The 
essential advantage of “we boost because we can” over 
sophisticated “dose painting by numbers” is, that it 
generates the data needed to reach said sophistication.  
From this pragmatic standpoint, neither today´s imaging 
capabilities nor the understanding of their relevance to 
tumour treatment response are sufficient to speak of an 
established biological rationale for DP. Some clinical 
evidence exists in few instances that links certain functional 
imaging to lack of tumour control or even location of 
recurrence. Given this, workable DP concepts today are 
rather shaped by considerations about image sensitivity and 
specificity and organ mobility, than biology. 
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Purpose/Objectives: This work aims at formally identifying 
the methodological issues that hinder the implementation 
and adoption of dose painting (DP) in radiotherapy. DP entails 
the use of functional imaging to set up a non-uniform dose 
escalation, either with sub-contours or voxel-to-voxel 
variations. Although theoretically appealing, DP has not 
succeeded yet in passing from research to clinical use. This 
work reviews the physical, mathematical, and statistical 
causes of this delay, in the specific case of DP guided by PET.  
 
Method: The following steps occur in PET-based DP: 
acquisition of PET images (before and/or during treatment, 
with one or several tracers), conversion of the uptake(s) into 
a dose increment, treatment plan optimization, fractionated 
treatment delivery, accumulation and assessment of the 
delivered dose, and optional treatment adaptation. Every 
step or piece of data in this path can be modeled to 
investigate its shortcomings. All PET tracers are 
characterized with their specificity and sensitivity as a 
surrogate of some biological variable of interest in given 
conditions (e.g., before or during radiotherapy). PET images 
are described by their resolution and signal-to-noise ratio. 
Treatment plan quality is assessed by a quality-volume 
histogram (QVH), namely, a DP-specific dose-volume 
histogram that considers the ratio planned dose over 
prescribed dose. Random and systematic patient setup errors 
are quantified with their respective standard deviation. Non-
rigid registration of pre- and per-treatment images is used to 
approximate the cumulated dose, taking into account patient 
evolution (tumor regression, possible weight loss).  
 
Results: Our main result is the formal proof that PET-based 
DP cannot lead to a delivered dose that is strongly correlated 
with the tracer uptake at the microscopic level. This weak 
correlation is caused by: i) The limited information conveyed 
by heterogeneities observed in PET images. Current PET 
systems have a low resolution and a low signal-to-noise ratio, 
